top of page

Affinity Bio Partners (ABP)

Founded in November 2014, in a transition from Christina DiArcangelo's previous company Armonia Clinical Research (first formed in 2009), ABP represents the world’s leading cutting-edge Clinical Research Organization (CRO).  Affinity Bio Partners LLC endeavors to provide integral enterprise-wide solutions that facilitate the development of drugs, biologics, natraceuticals and medical devices. 

ABP provides services such as, but not limited to:

  • Global Groundbreaking Medical Cannabis and Cannabinoid Clinical Research activities

  • Clinical Research Operations and Product Portfolio Development

  • Proven track record for subject recruitment and a true understanding of therapeutic areas through the partnership with Affinity Patient Advocacy

  • Enterprise-wide Strategic Mitigation Planning Solutions

  • Enterprise-wide Governance Solutions

  • Asset Procurement and Staffing Solutions

  • Advance clinical outsourcing to improve the quality, efficiency and safety of clinical research.

  • Conducting clinical trials in domestic and international settings while ensuring the safety of research participants.

  • Strengthen public understanding and confidence in clinical research, highlighting CRO expertise in all aspects of the clinical research services enterprise.

Affinity Bio Partner
Affinity Bio Partner

Our Mission

Affinity Bio Partners (ABP) and its affiliates ensure that on a global basis that clinical research is performed safely, ethically, with high-quality so that subjects can benefit from the development of new  and novel treatments and therapies. Our partners will find that ABP is dedicated to helping their clients bring efficiency, innovation and value to the clinical research process while staying on budget and pushing timelines ahead as aggressively as possible.

The Affinity Bio Partners CEO

Christina DiArcangelo

A Global, Award-Winning Entrepreneur and CEO with more than two decades of experience in the medical cannabis, biotechnology, pharmaceutical, nutraceutical, and medical device industries, Christina’s dedication to revolutionizing patient care is unprecedented. Through her roles as CEO, Spectral Analytics Precision Tele-Monitoring, Founder and CEO of Affinity Bio Partners, Board President and CEO of Affinity Patient Advocacy, Christina has been involved with revolutionary projects and global clinical studies that positively impact patients including formulating new products.  Christina has spoken at many events including delivering Keynote addresses as well as organizing her own education events for her multiple companies.

Christina has a personal brand, I am Christina DiArcangelo with a podcast channel, Season 1 - (I am Christina DiArcangelo) and Season 2 - (Humanitarian Horizons - Christina DiArcangelo Unveiled) where she speaks to many exciting, thought-provoking guests.  Christina has also developed merchandise under Affinity Patient Advocacy and Christina DiArcangelo and launched a merchandise company called Sparkle Sisters and is the CEO

Christina has launched an e-magazine called The DiArc.  The DiArc is a lifestyle magazine that shines a spotlight on all topics that apply to Christina DiArcangelo.

As an award winning global clinical research pioneer, and Christina is also an Opinion Columnist for CEO WorldBiz, she has utilized the tools at her disposal to champion patient care and provide best-in-class patient advocacy services. For Christina, patient care and safety come first.

As an active Bahai’ and mother to her one son, Christian, she believes that listening, learning, and growing are everyday values that can change the world by impacting our own hearts, homes, and communities.

Affinity Bio Partners LLC and Christina DiArcangelo have been leading voices for safe and ethical clinical trials while working with stakeholders globally to promote a better and more efficient clinical trial process.
bottom of page